KRAS and neoplasm: Experimental evidence supports that the immune landscape and vulnerabilities of various tumor types can rely on single mutated driver oncogenes such as KRAS and MYC that orchestrate distinct transcriptional programs, dictate a tumor’s specific pro-inflammatory mediator secretory profile, and largely define the cellular composition of the tumor microenvironment [6,7].